First Ever Biosimilar Approval in China: Trouble for Roche?
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
Address: 4th Floor, 4/B, 233 Zhen Ning Lu
Rong Xuan Building
200050 – Shanghai / CHINA
Tel: +(86) 151 1797 6292
Web: http://www.acropolis-associates.com/
We assist multinational organizations, small and medium sized enterprises as well as smaller niche companies to attract, recruit and retain outstanding executives and senior managers through our specialist search techniques as well as through our strategic leadership consultancy services.At Acropolis-Associates, our outstanding staff is committed to provide its clients with executives, professionals and specialists whose skills will enhance and improve your business performance and profitability.Acropolis-Associates, professional recruitment consultancy, is committed to deliver the very best talent to its international clients. We operate from offices covering USA, France and China. Our talented professionals pursue the highest level of integrity and quality in providing a clear portfolio of services: executive search, recruitment, placement, and staff integrity.For more than 9 years, Acropolis-Associates has been devoted in delivering its services to organizations by strengthening management teams and their international staff.
» Executive Search
» Recruitment / Placement
» Corporate Fraud Alert (CFA)
» Building an Ethical Framework (BEF)
» Staff & Suppliers Integrity investigation (SSII)
» Education, Study abroad (China – USA / China – Europe)
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
See our Cookie Privacy Policy Here
